News

Ask anyone in pharma why drugs fail, and you’ll hear the same story. Roughly nine out of ten candidates who enter Phase I never reach approval, mostly because they don’t work well enough or turn out to be unsafe. Years of effort and billions of dollars, gone. The research team based at Stanford University (the…

For years, the promise of artificial intelligence in drug discovery has lived mostly in press releases and conference decks. Researchers have talked about what AI could do — compress timelines, identify overlooked targets, and design better molecules. What we haven’t seen much of, until now, is an AI-designed drug actually walking through clinical trials with…